Sherbrooke Park Advisers’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-3,707
Closed -$204K 765
2024
Q4
$204K Sell
3,707
-3,809
-51% -$200K 0.07% 583
2024
Q3
$378K Buy
7,516
+2,775
+59% +$128K 0.09% 457
2024
Q2
$208K Buy
+4,741
New +$202K 0.04% 760

Other funds holding IRMD

Sherbrooke Park Advisers's IRMD Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of iRadimed (IRMD) in Q1 2025, closing a stake of 3,707 shares — an estimated $204K sold.

Sherbrooke Park Advisers first reported a position in IRMD in Q2 2024 and held it in 3 quarters. The position peaked at $378K in Q3 2024. 168 funds tracked by Wall St. Rank hold IRMD as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining iRadimed position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 3,707 iRadimed shares in Q1 2025, an estimated $204K.
  • Sherbrooke Park Advisers first reported a position in iRadimed in Q2 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's iRadimed position peaked at $378K in Q3 2024.
  • 168 funds tracked by Wall St. Rank held iRadimed as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.